Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection
Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection CAMBRIDGE, MA--(Marketwire - Jan 7, 2013) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, is
View HTML
Toggle Summary Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis
Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis CAMBRIDGE, MA--(Marketwire - Jan 3, 2013) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and
View HTML
Toggle Summary Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis
Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis Cambridge, Mass., December 20, 2012 – Radius Health , Inc. (“Radius”) and 3M Drug Delivery Systems are pleased to announce an exclusive partnership
View HTML
Toggle Summary Radius Health Withdraws Registration Statement
Radius Health Withdraws Registration Statement CAMBRIDGE, MA--(Marketwire - Nov 15, 2012) -   Radius Health , Inc. ("Radius"), announced today that it has voluntarily withdrawn its Registration Statement on Form S-1 (Registration No. 333-179397) (the "Registration Statement") that was filed on
View HTML
Toggle Summary Radius Health Announces Upcoming Scientific Presentations at the American Society for Bone and Mineral Research 2012 Annual Meeting
Radius Health Announces Upcoming Scientific Presentations at the American Society for Bone and Mineral Research 2012 Annual Meeting CAMBRIDGE, MA--(Marketwire - Oct 12, 2012) - Radius Health , Inc. ("Radius"), a biopharmaceutical company focused on developing new therapeutics for the treatment of
View HTML
Toggle Summary Radius Initiates Phase 2 Study of BA058-Transdermal for the Treatment of Postmenopausal Osteoporosis
Radius Initiates Phase 2 Study of BA058-Transdermal for the Treatment of Postmenopausal Osteoporosis Cambridge, MA, September 27, 2012 – Radius Health , Inc. (“Radius”) , a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health
View HTML
Toggle Summary Radius Health Announces Upcoming Scientific Presentations at ENDO 2012, the Endocrine Society's 94th Annual Meeting
Radius Health Announces Upcoming Scientific Presentations at ENDO 2012, the Endocrine Society's 94th Annual Meeting CAMBRIDGE, MA--(Marketwire - Jun 22, 2012) - Radius Health, a development-stage biopharmaceutical company focused on advanced therapies for healthy aging, will present scientific data
View HTML
Toggle Summary Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer
Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer CAMBRIDGE, Mass., April  20, 2011—   Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health
View HTML
Toggle Summary Radius Health, Inc. Files Registration Statement for Proposed Public Offering
Radius Health, Inc. Files Registration Statement for Proposed Public Offering CAMBRIDGE, MA--(Marketwire - Feb 7, 2012) - Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, today announced
View HTML
Toggle Summary Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal Treatment of Osteoporosis
Technical Feasibility Demonstrated for Transdermal Delivery of BA058; Study Endpoints of Pharmacokinetic Profile, Safety, and Tolerability Successfully Met; Results Support Plan for Future Phase 2 Proof-of-Concept Clinical Trial
View HTML